Kunming Longjin Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Kunming Longjin Pharmaceutical Co., Ltd. carries a market capitalization of 236.30M, placing it among publicly traded companies globally. Its enterprise value stands at 321.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 236.30M |
| Enterprise Value | 321.13M |
Share Statistics
Kunming Longjin Pharmaceutical Co., Ltd. currently has 400.50M shares outstanding.
| Shares Outstanding | 400.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12.35, and the price-to-book ratio stands at 1.37.
| PE Ratio | N/A |
| PS Ratio | 12.35 |
| PB Ratio | 1.37 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | 35.09 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 6.98 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 19.57 |
Financial Position
Kunming Longjin Pharmaceutical Co., Ltd. maintains a current ratio of 7.94, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.53, indicating moderate leverage, while an interest coverage ratio of -127.69 demonstrates limited ability to service its debt obligations.
| Current Ratio | 7.94 |
| Quick Ratio | 6.90 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | -0.09 |
| Interest Coverage | -127.69 |
Financial Efficiency
| Return on Equity (ROE) | -9.41 |
| Return on Assets (ROA) | -6.86 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.69 |
Taxes
| Income Tax | 2.52M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Kunming Longjin Pharmaceutical Co., Ltd.'s stock has declined approximately -72.55814% over the past 52 weeks. The 50-day moving average sits at 0.98, while the 200-day moving average is 1.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | -72.55814% |
| 50-Day Moving Average | 0.98 |
| 200-Day Moving Average | 1.71 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kunming Longjin Pharmaceutical Co., Ltd. generated 45.99M in revenue and converted that into -41.03M in net income, yielding earnings per share of -0.12. EBITDA reached -27.53M, while operating income came in at -27.53M.
| Revenue | 45.99M |
| Gross Profit | 28.28M |
| Operating Income | -27.53M |
| Pretax Income | -43.78M |
| Net Income | -41.03M |
| EBITDA | -27.53M |
| EBIT | -27.53M |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
Kunming Longjin Pharmaceutical Co., Ltd. holds 270.29M in cash and equivalents against 2.57M in total debt, resulting in a net debt position of -50.85M. Total book value stands at 415.37M, with working capital of 271.92M providing operational flexibility.
| Cash & Cash Equivalents | 270.29M |
| Total Debt | 2.57M |
| Net Debt | -50.85M |
| Equity (Book Value) | 415.37M |
| Book Value Per Share | 1.04 |
| Working Capital | 271.92M |
Cash Flow
After subtracting -16.18M in capital expenditures, free cash flow totaled -16.18M - equivalent to -0.04 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -16.18M |
| Free Cash Flow | -16.18M |
| FCF Per Share | -0.04 |
Margins
Kunming Longjin Pharmaceutical Co., Ltd. operates with a gross margin of 61.49, reflecting its pricing power and cost economics. The operating margin of -59.86 and net profit margin of -89.21 provide insight into operational efficiency.
| Gross Margin | 61.49 |
| Operating Margin | -59.86 |
| Pretax Margin | -95.19 |
| Profit Margin | -89.21 |
| EBITDA Margin | -59.86 |
Dividends & Yields
The company's payout ratio of -0.13 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | -0.13 |
| Shareholder Yield | 1.82 |
| FCF Yield | 2.85 |
Stock Splits
Kunming Longjin Pharmaceutical Co., Ltd.'s most recent stock split took place on May 18, 2016 with a 1:2 split ratio.
| Last Split Date | 5/18/2016 |
| Split Ratio | 1:2 |
Scores
Kunming Longjin Pharmaceutical Co., Ltd. posts an Altman Z-Score of 5.50, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.50 |